Amneal Pharmaceuticals
AMRX · NYSE
Share price · AMRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AMRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 21 Sep 2026+7.7%
- 16 Sep 2026+8.6%
Nothing announced by AMRX that day or the session before.
- 14 Aug 2026+5.1%
Nothing announced by AMRX that day or the session before.
- 16 Jul 2026+4.9%
Nothing announced by AMRX that day or the session before.
- 10 Jun 2026+4.3%
Nothing announced by AMRX that day or the session before.
- 9 Jun 2026+7.1%
Nothing announced by AMRX that day or the session before.
- 8 May 2026-3.8%
- 20 Apr 2026-4.7%
- 17 Apr 2026+6.3%
Nothing announced by AMRX that day or the session before.
- 17 Mar 2026+4.1%
Nothing announced by AMRX that day or the session before.
Share of unusual movement by asset
For each asset, the share of AMRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer | |
| Approved | dopamine precursorSmall molecule | Parkinson's Disease | |
| Approved | 5-HT1D receptorSmall molecule | Migraine | |
Opicapone(Ongentys) | Approved | COMTSmall molecule | Parkinson's Disease |
| Approved | dopamine precursorSmall molecule | Parkinson's Disease | |
| Approved | 5-HT1B/1D receptorsSmall molecule | Migraine |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $863M | $68M | $180M | $22M$98M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $796M | $39M | $140M | —-$21M operating cash flow | report ↗ |
| 2026-Q1 | $723M | $38M | $204M | —-$27M operating cash flow | report ↗ |
| 2025-Q3 | $785M | $63M | $238M | —$118M operating cash flow | report ↗ |
| 2025-Q2 | $725M | $48M | $84M | —$84M operating cash flow | report ↗ |
| 2025-Q1 | $695M | $40M | $68M | —$7.4M operating cash flow | report ↗ |
| 2024-Q3 | $702M | $61M | $78M | $0.2M$142M operating cash flow | report ↗ |
| 2024-Q2 | $702M | $36M | $50M | —$40M operating cash flow | report ↗ |
| 2024-Q1 | $659M | $39M | $52M | $92M-$4.4M operating cash flow | report ↗ |
| 2023-Q3 | $620M | $41M | $96M | —$81M operating cash flow | report ↗ |
| 2023-Q2 | $599M | $38M | $115M | —-$11M operating cash flow | report ↗ |
| 2023-Q1 | $558M | $39M | $151M | $16M$140M operating cash flow | report ↗ |
| 2022-Q3 | $546M | $50M | $96M | $7.6M$94M operating cash flow | report ↗ |
| 2022-Q2 | $559M | $51M | $98M | $242M-$126M operating cash flow | report ↗ |
| 2022-Q1 | $498M | $53M | $217M | $8.8M$120M operating cash flow | report ↗ |
| 2021-Q3 | $529M | $49M | $311M | $7.8M$82M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.0B | $186M | $313M | —$340M operating cash flow | report ↗ |
Amneal reported full-year 2025 revenue of $3,018.76M, up 8.0% YoY, with R&D spend of $186.18M, down 2.4% YoY, and cash and equivalents of $312.94M. Net income attributable to the company was $72.06M, with GAAP diluted EPS of $0.22.
Management provided 2026 guidance for net revenue of $3.05–$3.15B, Adjusted EBITDA of $720–$760M, and Adjusted diluted EPS of $0.93–$1.03. The company highlighted continued CREXONT uptake, the BREKIYA autoinjector launch, its first two inhalation products, and its fourth and fifth biosimilars.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 5 sales ($7.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-17 | BUCHI J KEVIN · director | Gift | 20,445 | — | — | Form 4 |
| 2026-09-11 | BUCHI J KEVIN · director | Option exercise | 20,445 | $14.45 | $295K | Form 4 |
| 2026-09-11 | BUCHI J KEVIN · director | Option exercise (derivative) | 20,445 | — | — | Form 4 |
| 2026-09-01 | BOYER ANDREW S · Executive Vice President | Gift | 80,000 | — | — | Form 4 |
| 2026-08-21 | BOYER ANDREW S · Executive Vice President | Gift | 152,426 | — | — | Form 4 |
| 2026-08-13 | Kiely John · director | Open-market sale | 50,000 | $17.64 | $882K | Form 4 |
| 2026-08-13 | Kiely John · director | Gift | 10,000 | — | — | Form 4 |
| 2026-08-12 | Shah Nikita · Executive Vice President | Open-market sale | 146,403 | $17.51 | $2.6M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 314 reporting institutions held 159.8M shares ($1.9B).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 24,519,192 | $304.8M |
| 2 | TPG GP A, LLC | 12,328,767 | $153.2M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11,324,933 | $140.8M |
| 4 | Rubric Capital Management LP | 11,037,589 | $137.2M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 7,585,034 | $94.3M |
| 6 | STATE STREET CORP | 6,794,702 | $84.5M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 5,690,586 | $70.7M |
| 8 | MORGAN STANLEY | 4,637,185 | $57.6M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 4,546,048 | $56.5M |
| 10 | NEUBERGER BERMAN GROUP LLC | 3,682,284 | $45.7M |
| 11 | Nuveen, LLC | 3,243,643 | $40.3M |
| 12 | Invesco Ltd. | 3,188,659 | $39.6M |
| 13 | Assenagon Asset Management S.A. | 3,067,361 | $38.1M |
| 14 | GOLDMAN SACHS GROUP INC | 2,863,860 | $35.6M |
| 15 | Nantahala Capital Management, LLC | 2,844,108 | $35.4M |